BPTH vs. CING, SPRB, NRSN, HCWB, BGXX, IMNN, HOTH, AIM, CRVO, and FLGC
Should you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Cingulate (CING), Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Bright Green (BGXX), Imunon (IMNN), Hoth Therapeutics (HOTH), AIM ImmunoTech (AIM), CervoMed (CRVO), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry.
Bio-Path vs.
Bio-Path (NASDAQ:BPTH) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Bio-Path received 273 more outperform votes than Cingulate when rated by MarketBeat users. However, 75.00% of users gave Cingulate an outperform vote while only 53.82% of users gave Bio-Path an outperform vote.
In the previous week, Bio-Path had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Cingulate. Cingulate's average media sentiment score of 0.00 beat Bio-Path's score of -1.00 indicating that Cingulate is being referred to more favorably in the news media.
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 17.1% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Bio-Path currently has a consensus price target of $20.00, indicating a potential upside of 2,339.02%. Cingulate has a consensus price target of $12.00, indicating a potential upside of 152.10%. Given Bio-Path's higher probable upside, research analysts clearly believe Bio-Path is more favorable than Cingulate.
Cingulate's return on equity of -570.20% beat Bio-Path's return on equity.
Bio-Path has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.
Summary
Cingulate beats Bio-Path on 9 of the 14 factors compared between the two stocks.
Get Bio-Path News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Path Competitors List
Related Companies and Tools
This page (NASDAQ:BPTH) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BPTH Stock Alerts